Therapy enhancing chromosome instability may be advantageous for IDH1 R132H/WT gliomas
NAR Cancer · 2025
DOI: 10.1093/narcan/zcaf003 ↗Kurz gefasst
Fachartikel in der Zeitschrift NAR Cancer, 2025. Verfasst von Nikolay V Goncharov und 12 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine and Life Sciences, Far Eastern Federal University, Vladivostok 690922, Russia. Hauptthemen laut MEDLINE: Glioma, Isocitrate Dehydrogenase, Chromosomal Instability, Brain Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Russian Science Foundation, Ministry of Science and Higher Education of the Russian Federation.
Abstract (Originalsprache)
Recently revised brain tumor classification suggested a glioma treatment strategy that takes into consideration molecular variants in IDH1 and TP53 marker genes. While pathogenic variants of IDH1 and TP53 can be accompanied by chromosomal instability (CIN), the impact of IDH1 and TP53 mutations on genome stability remains unstudied. Elevated CIN might provide therapeutic targets, based on synergistic effects of chemotherapy with CIN-inducing drugs. Using an assay based on human artificial chromosomes, we investigated the impact of common glioma missense mutations in IDH1 and TP53 on chromosome transmission and demonstrated that IDH1R132H and TP53R248Q variants elevate CIN. We next found enhanced CIN levels and the sensitivity of IDH1R132H/WT and TP53R248Q/R248Q genotypes, introduced into U87 MG glioma cells by CRISPR/Cas9, to different drugs, including conventional temozolomide. It was found that U87 MG cells carrying IDH1R132H/WT exhibit dramatic sensitivity to paclitaxel, which was independently confirmed on cell cultures derived from patients with naturally occurring IDH1R132H/WT. Overall, our results suggest that the development of CIN-enhancing therapy for glioma tumors with the IDH1R132H/WT genotype could be advantageous for adjuvant treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Medicine and Life Sciences, Far Eastern Federal University, Vladivostok 690922, Russia.
- A.V. Zhirmunsky National Scientific Center of Marine Biology, Far Eastern Branch, Russian Academy of Sciences, Vladivostok 690041, Russia.
- Neuro-Oncology Branch, National Cancer Institute, NIH, Bethesda, MD 20892, United States.
- Developmental Therapeutics Branch, National Cancer Institute, NIH, Bethesda, MD 20892, United States.
ORCID-Profile: Nikolay V Goncharov, Ivan N Baklanov, Anastasiia P Shuliak, Daria V Lanskikh, Mikhail E Shmelev, Jing Wu, Mikhail Liskovykh, Natalay Kouprina, Vadim V Kumeiko
Förderung
- Russian Science Foundation
- Ministry of Science and Higher Education of the Russian Federation
Zitieren
APA
Goncharov, N. V., Baklanov, I. N., Gulaia, V. S., Shuliak, A. P., Lanskikh, D. V., Zhmenia, V. M., Shmelev, M. E., Shved, N. A., Wu, J., Liskovykh, M., Larionov, V., Kouprina, N., & Kumeiko, V. V. (2025). Therapy enhancing chromosome instability may be advantageous for IDH1 R132H/WT gliomas. NAR Cancer. https://doi.org/10.1093/narcan/zcaf003
Vancouver
Goncharov NV, Baklanov IN, Gulaia VS, Shuliak AP, Lanskikh DV, Zhmenia VM, et al. Therapy enhancing chromosome instability may be advantageous for IDH1 R132H/WT gliomas. NAR Cancer. 2025. doi:10.1093/narcan/zcaf003
BibTeX
@article{Goncharov2025,
author = {Goncharov, Nikolay V and Baklanov, Ivan N and Gulaia, Valeriia S and Shuliak, Anastasiia P and Lanskikh, Daria V and Zhmenia, Valeriia M and Shmelev, Mikhail E and Shved, Nikita A and Wu, Jing and Liskovykh, Mikhail and Larionov, Vladimir and Kouprina, Natalay and Kumeiko, Vadim V},
title = {Therapy enhancing chromosome instability may be advantageous for IDH1 R132H/WT gliomas},
journal = {NAR Cancer},
year = {2025},
doi = {10.1093/narcan/zcaf003}
}
EUVIMED